GleanMark

QURE Trademark

QURE is a USPTO trademark filed by uniQure IP B.V.. Status: Pending.

Trademark Facts

MarkQURE
Serial Number98371742
StatusPending
Filing Date2024-01-23
Mark TypeWord
Nice Classes001 (Chemicals), 005 (Pharmaceuticals), 042 (Software & IT), 044 (Medical Services)
OwneruniQure IP B.V.
Attorney of RecordErica R. Halstead
Prosecution Events34
Latest EventTEME on 2026-05-05

Goods & Services

Viral systems, gene therapy systems, nucleic acid delivery systems, all comprised of biological preparations in the nature of viruses for medical purposes; viral vectors, gene therapy vectors, nucleic acid delivery vectors, all comprised of biological preparations in the nature of viruses for medical purposes; pharmaceutical products for the treatment of diseases; biological preparations for use in medical purposes, namely, in medical and clinical gene therapy, nucleic acid-based therapy; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, gene diagnosis and gene testing; pharmaceutical preparations being prophylaxis products for use in nucleic acid-based therapy and gene therapy; Viral systems, gene therapy systems, and nucleic acid delivery systems, all comprised of biological preparations in the nature of viruses for use in cell cultures for non-medical, scientific research purposes; viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors and nucleic acid delivery vectors all comprised of biological preparations in the nature of viruses for use in cell cultures for non-medical, scientific research purposes; Medical treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders using gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation; Providing medical information and advice in the field of medical treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders using gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation; Medical and scientific research, product development and consultancy in the fields of biotechnology, biology, biopharmaceutical research and development, medical science, chemistry and biochemistry; Providing medical and scientific research information and advice in the fields of biotechnology, biology, biopharmaceutical research and development, medical science, chemistry and biochemistry

Recent Prosecution Activity

DateDocumentType
2026-05-05Response to Office ActionROA
2026-04-17Notice of Non-Final Office ActionNFO
2026-04-17Non-Final ActionNFIN
2026-03-28Amendment and Mail Process CompleteAMC
2026-03-27TEAS Response to Suspension InquiryRSI
2025-12-18Suspension LetterSUSLT

USPTO Refusals on Record

Related